3 Risers on Good News for Tuesday 21st February 2023
Episode 1199, Feb 21, 2023, 09:21 AM
3 Risers on Good News for Tuesday 21st February 2023
1. Blancco Technology #BLTG - Interim Results
Blancco Technology Group, the industry standard in data erasure and mobile lifecycle solutions, is pleased to announce its interim results for the six months ended 31 December 2022.
Highlights
- Revenue £24m up from £19.7m an increase of +22%
- Operating profit was up 42% from £1.9m to £2.7m
- Cash of £8.4m.
Matt Jones, Chief Executive of Blancco:
"These results for the first six months of the financial year show strong double-digit growth in revenue, profit and cash despite the macro-economic challenges seen in many of the territories in which we operate.
Existing and upcoming regulation on data security coupled with near-term legislation on sustainability means Blancco's proposition is more relevant than ever before, and the Board remains confident in the continued growth prospects of the company."
2. Zoo Digital #ZOO - Contract with major Hollywood studio
ZOO Digital #ZOO, a world-leading provider of cloud-based localisation and media services, today announced it is now operating as a key vendor for a major Hollywood content producer to support their content localisation needs. This client is also using ZOOstudio to manage the localisation of content across its vendors.
The adoption of ZOOstudio by another global content creator, which cannot be named for contractual reasons, represents a further success story for ZOO as a strategic technology partner. While longer-term contractual arrangements have not yet been finalised, a significant number of revenue-generating projects for this client are already underway.
3. Scancell Holdings #SCLP - Encouraging early efficacy data from ModiFY trial
Scancell Holdings #SCLP, the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces completion of the monotherapy dose finding arm of the multicentre Phase 1/2 ModiFY clinical trial.
Data from patients receiving the Modi-1 cancer vaccine as a monotherapy showed that it was safe and well tolerated and demonstrated encouraging early efficacy in a head and neck cancer patient and in other hard-to-treat cancers such as high grade serous ovarian carcinoma (HGSOC) and triple negative breast cancer (TNBC).
1. Blancco Technology #BLTG - Interim Results
Blancco Technology Group, the industry standard in data erasure and mobile lifecycle solutions, is pleased to announce its interim results for the six months ended 31 December 2022.
Highlights
- Revenue £24m up from £19.7m an increase of +22%
- Operating profit was up 42% from £1.9m to £2.7m
- Cash of £8.4m.
Matt Jones, Chief Executive of Blancco:
"These results for the first six months of the financial year show strong double-digit growth in revenue, profit and cash despite the macro-economic challenges seen in many of the territories in which we operate.
Existing and upcoming regulation on data security coupled with near-term legislation on sustainability means Blancco's proposition is more relevant than ever before, and the Board remains confident in the continued growth prospects of the company."
2. Zoo Digital #ZOO - Contract with major Hollywood studio
ZOO Digital #ZOO, a world-leading provider of cloud-based localisation and media services, today announced it is now operating as a key vendor for a major Hollywood content producer to support their content localisation needs. This client is also using ZOOstudio to manage the localisation of content across its vendors.
The adoption of ZOOstudio by another global content creator, which cannot be named for contractual reasons, represents a further success story for ZOO as a strategic technology partner. While longer-term contractual arrangements have not yet been finalised, a significant number of revenue-generating projects for this client are already underway.
3. Scancell Holdings #SCLP - Encouraging early efficacy data from ModiFY trial
Scancell Holdings #SCLP, the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces completion of the monotherapy dose finding arm of the multicentre Phase 1/2 ModiFY clinical trial.
Data from patients receiving the Modi-1 cancer vaccine as a monotherapy showed that it was safe and well tolerated and demonstrated encouraging early efficacy in a head and neck cancer patient and in other hard-to-treat cancers such as high grade serous ovarian carcinoma (HGSOC) and triple negative breast cancer (TNBC).